Zydus Lifesciences gets EIR for formulations manufacturing facility in Moraiya from USFDA

07 Nov 2022 Evaluate

Zydus Lifesciences (including its subsidiaries, together referred to as ‘Zydus’), an innovation driven global lifesciences company has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility in Moraiya, near Ahmedabad, India. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). The USFDA had inspected the facility from July 26 to August 05, 2022 which concluded with four observations. The USFDA has indicated that the inspection is closed.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

867.80 -16.20 (-1.83%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×